| Rimonabant | cardiovascular prevention, in overweight or obese patients | vs placebo | weight loss equal to or greater than 5 percent by 151% suggested weight loss equal to or greater than 10 percent by 245% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| weight loss equal to or greater than 5 percent | 2.51 [2.08 3.03] | p=0.04 | 0 | 2733 | 2 | RIO europe 20mg, RIO-North America 20 mg, | | weight loss equal to or greater than 10 percent | 3.45 [2.75 4.33] | p=0.04 | 0 | 3421 | 3 | RIO europe 20mg, Rio-lipid 20 mg, RIO-North America 20 mg, |
| Trial | Studied treatment | Control | Patients |
|---|
| RIO europe 20mg, 2005 | rimonabant 20mg daily | placebo | patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or bothtž-dt | | Rio-lipid 20 mg, 2005 | rimonabant 20 mg daily | placebo | overweight or obese patients (body-mass index 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men) | | RIO-North America 20 mg, 2006 | rimonabant 20mg daily | placebo | obese (body mass index >=30) or overweight (body mass index >=27 and treated or untreated hypertension or dyslipidemia) adult patients | | RIO europe 5mg, 2005 | 5 mg rimonabant | placebo | patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or both | | CRESCENDO, 2010 | rimonabant 20 mg | placebo | patients patients with abdominal obesity and with previously manifest or increased risk of vascular disease |
| |
